MX2022014067A - Enzimas con dominios ruvc. - Google Patents

Enzimas con dominios ruvc.

Info

Publication number
MX2022014067A
MX2022014067A MX2022014067A MX2022014067A MX2022014067A MX 2022014067 A MX2022014067 A MX 2022014067A MX 2022014067 A MX2022014067 A MX 2022014067A MX 2022014067 A MX2022014067 A MX 2022014067A MX 2022014067 A MX2022014067 A MX 2022014067A
Authority
MX
Mexico
Prior art keywords
enzymes
ruvc domains
ruvc
domains
variants
Prior art date
Application number
MX2022014067A
Other languages
English (en)
Spanish (es)
Inventor
Jason Liu
Christopher Brown
Brian Thomas
Rose Kantor
Audra Devoto
Cristina Butterfield
Lisa Alexander
Daniela S A Goltsman
Greg Cost
Rebecca Lamothe
Diego Espinosa
Meghan Storlie
Original Assignee
Metagenomi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagenomi Inc filed Critical Metagenomi Inc
Publication of MX2022014067A publication Critical patent/MX2022014067A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/80Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2022014067A 2020-05-08 2021-05-06 Enzimas con dominios ruvc. MX2022014067A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063022320P 2020-05-08 2020-05-08
US202063032464P 2020-05-29 2020-05-29
US202063116155P 2020-11-19 2020-11-19
US202163180570P 2021-04-27 2021-04-27
PCT/US2021/031136 WO2021226363A1 (en) 2020-05-08 2021-05-06 Enzymes with ruvc domains

Publications (1)

Publication Number Publication Date
MX2022014067A true MX2022014067A (es) 2023-02-22

Family

ID=78468763

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014067A MX2022014067A (es) 2020-05-08 2021-05-06 Enzimas con dominios ruvc.

Country Status (10)

Country Link
US (1) US20240209332A1 (https=)
EP (2) EP4467642A3 (https=)
JP (2) JP7778087B2 (https=)
KR (1) KR20230021657A (https=)
CN (1) CN116096892A (https=)
AU (1) AU2021267379A1 (https=)
CA (1) CA3177828A1 (https=)
GB (1) GB2612458B (https=)
MX (1) MX2022014067A (https=)
WO (1) WO2021226363A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178933A2 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10913941B2 (en) * 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
WO2021202568A1 (en) 2020-03-31 2021-10-07 Metagenomi Ip Technologies, Llc Class ii, type ii crispr systems
CA3205865A1 (en) * 2021-01-22 2022-07-28 Brian C. Thomas Novel engineered and chimeric nucleases
AU2022335499A1 (en) 2021-08-27 2024-02-22 Metagenomi Therapeutics, Inc. Enzymes with ruvc domains
AU2022396533A1 (en) 2021-11-24 2024-05-02 Metagenomi Therapeutics, Inc. Endonuclease systems
CA3243006A1 (en) * 2021-12-21 2025-02-27 Alia Therapeutics Srl TYPE II CAS PROTEINS AND THEIR APPLICATIONS
WO2023137451A1 (en) * 2022-01-14 2023-07-20 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting cd38 and uses thereof
WO2023194359A1 (en) * 2022-04-04 2023-10-12 Alia Therapeutics Srl Compositions and methods for treatment of usher syndrome type 2a
CA3267752A1 (en) * 2022-09-16 2024-03-21 Alia Therapeutics Srl ENQP TYPE II CAS PROTEINS AND THEIR APPLICATIONS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015161276A2 (en) * 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
EP3423580A1 (en) * 2016-03-04 2019-01-09 Editas Medicine, Inc. Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
US20190136230A1 (en) * 2016-05-06 2019-05-09 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
EP3500967A1 (en) * 2016-08-17 2019-06-26 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
WO2018073393A2 (en) * 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
EP3617311B1 (en) * 2017-03-30 2024-11-20 Kyoto University Method for inducing exon skipping by genome editing
MX2019013514A (es) * 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
US9982279B1 (en) * 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
EP3724326A1 (en) * 2017-12-11 2020-10-21 Editas Medicine, Inc. Cpf1-related methods and compositions for gene editing
WO2019165168A1 (en) * 2018-02-23 2019-08-29 Pioneer Hi-Bred International, Inc. Novel cas9 orthologs
CA3094468A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
AU2019252925A1 (en) * 2018-04-13 2020-07-30 Sigma-Aldrich Co. Llc. Modification of immune-related genomic loci using paired CRISPR nickase ribonucleoproteins
CN113227374A (zh) * 2018-10-16 2021-08-06 因特利亚治疗公司 用于免疫疗法的组合物和方法
CA3241703C (en) * 2019-02-14 2026-02-24 Metagenomi Therapeutics, Inc. Enzymes with ruvc domains
JP2024515936A (ja) * 2021-03-19 2024-04-11 メタゲノミ,インク. Cas酵素を用いたマルチプレックス編集

Also Published As

Publication number Publication date
KR20230021657A (ko) 2023-02-14
GB202217378D0 (en) 2023-01-04
CA3177828A1 (en) 2021-11-11
JP7778087B2 (ja) 2025-12-01
CN116096892A (zh) 2023-05-09
AU2021267379A1 (en) 2022-12-08
EP4467642A2 (en) 2024-11-27
EP4146800A1 (en) 2023-03-15
JP2023533417A (ja) 2023-08-03
GB2612458B (en) 2025-04-09
EP4467642A3 (en) 2025-04-16
WO2021226363A1 (en) 2021-11-11
JP2025090617A (ja) 2025-06-17
US20240209332A1 (en) 2024-06-27
GB2612458A (en) 2023-05-03

Similar Documents

Publication Publication Date Title
MX2022014067A (es) Enzimas con dominios ruvc.
GB2605340A8 (en) Base editing enzymes
MX2022012110A (es) Sistemas crispr clase ii tipo ii.
WO2022232638A3 (en) Enzymes with ruvc domains
MX2021009886A (es) Enzimas con dominios ruvc.
MX2024005505A (es) Enzimas de edicion de bases.
EP4328241A3 (en) Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
WO2020252229A3 (en) Inhibitors of sarm1
MX2016001315A (es) Variantes de enzimas.
WO2018160995A8 (en) COMPOSITION AND METHODS FOR ENHANCED MICROBIAL DIGESTION OF POLYMERS IN HYDRAULIC FRACTURING WELLS
PH12021550558A1 (en) Modulators of pnpla3 expression
WO2020051375A3 (en) Papd5 inhibitors and methods of use thereof
MY189867A (en) Solubilization of msw with blend enzymes
MX2025003294A (es) Moduladores de la expresion de apol1
EP4309732A3 (en) Modulators of pcsk9 expression
WO2017076421A9 (en) Solubilization of msw with blend enzymes
WO2020104649A3 (en) Novel rna compositions and methods for inhibiting angptl8
MX2024002539A (es) Enzimas con dominios ruvc.
GB2615901A8 (en) Base editing enzymes
MX2022014126A (es) Moduladores de enpp1 y usos de los mismos.
ZA202105742B (en) Modulators of malat1 expression
MX2020010721A (es) Moduladores de la expresion de ezh2.
MX2024014079A (es) Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos
PH12021551053A1 (en) Modulators of irf5 expression
MX2025010221A (es) Enzimas con dominios ruvc